Changeflow GovPing Healthcare & Life Sciences GDF-15 Monoclonal Antibodies European Patent Ap...
Routine Notice Added Final

GDF-15 Monoclonal Antibodies European Patent Application EP3590537A1

Favicon for changeflow.com EPO Patent Bulletin - Pharma (A61K)
Published
Detected
Email

Summary

European Patent Application EP3590537A1 for monoclonal antibodies targeting Growth and Differentiation Factor 15 (GDF-15) was published by the European Patent Office on April 15, 2026. The applicant is Julius-Maximilians-Universität Würzburg (Germany), with inventors Wischhusen, Junker, Müller, and Saremba. The application is classified under A61K 39/395 and C07K 16/22 and designates all EU member states plus several additional European countries.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors EPO Patent Bulletin - Pharma (A61K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 58 changes logged to date.

What changed

The European Patent Office published Application EP3590537A1 for monoclonal antibodies against Growth and Differentiation Factor 15 (GDF-15), classified under IPC codes A61K 39/395 and C07K 16/22. The application names Julius-Maximilians-Universität Würzburg as applicant and four named inventors. The designation covers all EU member states plus additional European contracting states.\n\nPharmaceutical and biotechnology companies developing GDF-15 targeted therapies should review the patent claims to assess freedom-to-operate implications. Research institutions and drug developers working in the GDF-15/oncology or metabolic disease space may need to evaluate whether their activities fall within the scope of the claimed antibodies.

Archived snapshot

Apr 24, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

MONOCLONAL ANTIBODIES TO GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15)

Publication EP3590537A1 Kind: A1 Apr 15, 2026

Applicants

Julius-Maximilians-Universität Würzburg

Inventors

Wischhusen, Prof. Dr. Jörg, Junker, Markus, Müller, Thomas, Saremba, Stefan

IPC Classifications

A61K 39/395 20060101AFI20191113BHEP C07K 16/22 20060101ALI20191113BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 15th, 2026
Instrument
Notice
Branch
International
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Pharmaceutical companies Healthcare providers Researchers and institutions conducting GDF-15 related research should review the patent claims for freedom-to-operate implications.
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology 6211 Healthcare Providers
Activity scope
Patent application publication Monoclonal antibody technology GDF-15 research
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare Public Health

Get alerts for this source

We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!